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Abstract
Background: We aimed to determine the reliability and validity of a hepatitis symptom inventory and to identify
predictors of hepatitis C (HCV) treatment initiation in a cohort of HIV-infected patients.
Methods: Prospective clinic based study that enrolled patients referred for HCV therapy consideration. A hepatitis
symptom inventory and the Center for Epidemiologic Studies Depression Scale (CES-D) were administered to HIV/
HCV individuals. The symptom inventory was factor analyzed and subscale reliability estimated with Cronbach’s
alpha. Predictive validity was evaluated using generalized estimating equations (GEE). Predictors of HCV treatment
were identified using logistic regression.
Results: Between April 2008 to July 2010, 126 HIV/HCV co-infected patients were enrolled in the study. Factor
analysis using data from 126 patients yielded a three-factor structure explaining 60% of the variance for the
inventory. Factor 1 (neuropsychiatric symptoms) had 14 items, factor 2 (somatic symptoms) had eleven items, and
factor 3 (sleep symptoms) had two items, explaining 28%, 22% and 11% of the variance, respectively. The three
factor subscales demonstrated high intrinsic consistency reliability. GEE modeling of the 32 patients who initiated
HCV therapy showed that patients developed worsening neuropsychiatric and somatic symptoms following HCV
therapy with stable sleep symptoms. Bivariate analyses identified the following as predictors of HCV therapy
initiation: lower HIV log10 RNA, lower scores for neuropsychiatric, somatic and sleep symptoms, lower CES-D scores
and white ethnicity. In stepwise multiple logistic regression analysis, low neuropsychiatric symptom score was the
strongest independent predictor of HCV therapy initiation and HIV log10 RNA was inversely associated with a
decision to initiate HCV treatment.
Conclusions: A 41-item hepatitis-related symptom inventory was found to have a clinically meaningful 3-factor
structure with excellent internal consistency reliability and predictive validity. In adjusted analysis, low
neuropsychiatric symptom scores and controlled HIV infection were independent predictors of HCV treatment
initiation. The usefulness of the HCV symptom inventory in monitoring HCV treatment should be evaluated
prospectively.
Background
Hepatitis C (HCV) co-infection in HIV-infected patients
has a more rapid progression to liver fibrosis, cirrhosis,
and ultimately death despite well controlled HIV infec-
tion [1-3]). Thus, HCV has become a priority in the
care of HIV individuals co-infected with HCV in USA
and Europe since 2005 [4,5]. However, the proportion of
co-infected HCV/HIV individuals who initiate HCV
therapy remains less than 25% in the USA after more
than five years of available dual therapy with pegylated
interferon and ribavirin [6,7]. Multiple medical and psy-
chosocial barriers that HIV patients face at any given
time in their care accounts for this low proportion of
HCV treatment initiation [8-10]. Furthermore, the
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among HCV/HIV patients [11,12]. Current standard
protocols for the assessment of HCV treatment eligibil-
ity incorporate routine screening of depression [13],
However, HCV/HIV patients often have multiple non-
specific symptoms referred as ‘somatic symptoms’ that
may or not be related to hidden depression [12]. Of
note, up to 47% of HCV/HIV patients discontinue ther-
apy due to worsening of underlying symptoms aggra-
vated by HCV therapy [14-16]. Currently there is lack of
standardization for assessment of these symptoms
among HCV/HIV patients being considered for HCV
treatment initiation.
In April 2008, a multidisciplinary hepatitis-HIV co-
infection program was established at the University Cali-
f o r n i a ,S a nD i e g o( U C S D )a sp a r to fac o m p r e h e n s i v e
HIV primary care system (Owen Clinic). We recognized
that HCV treatment side effects may influence treat-
ment initiation decisions and also affect treatment
adherence and completion [17]. We therefore set out an
exploratory analysis to evaluate a HCV symptom inven-
tory in a population of HIV-coinfected patients referred
for HCV treatment. The aims of this study were: 1) to
determine the reliability and validity of a HCV symptom
inventory and 2) to identify predictors of HCV treat-
ment initiation in a cohort of HIV patients referred for
HCV treatment.
Methods
Study design
This prospective study was conducted on patients
referred to the UCSD Owen Hepatitis Co-infection
clinic for the assessment of HCV treatment eligibility.
The psychometric properties of the HCV symptom
inventory were studied using data from this longitudinal
cohort. The study was approved by the UCSD Human
Research Protection Program (project# 071931). All
patients upon Owen Clinic enrollment provided written
informed consent for the collection of data relevant to
their clinical care and subsequent analysis. This study
was conducted according to the principles expressed in
the Declaration of Helsinki.
Inclusion criteria and study enrollment
Patients diagnosed with HCV/HIV co-infection either by
HCV ELISA antibody and/or HCV polymerase chain
reaction were referred to the UCSD Owen Hepatitis Co-
infection Clinic for staging of HCV infection and assess-
ment of treatment eligibility. Participants enrolled in the
present study were required to: (1) read and understand
English; (2) fulfill minimal clinical criteria for HCV
treatment eligibility according to our clinic protocol (see
below); (3) complete HCV clinical staging process; and
(4) be willing to complete study survey instruments.
Clinical assessment of Hepatitis C treatment eligibility
Our minimal requirements for HCV treatment eligibility
were: (1) undetectable HIV viral loads and CD4 cell
counts above 200/cm
3 if on antiretroviral therapy; (2)
CD4 cell count above 500/cm
3 irrespective of HIV viral
load value if naïve to antiretroviral therapy; (3) absence
of liver cirrhosis; (4) stable medical comorbidities; (5)
favorable recommendation from the team’s psychiatrist
who performed independent evaluations of every patient
regardless of prior psychiatric history; (6) registration in
the San Diego needle exchange program in the case of
ongoing parenteral illicit substance use with documenta-
tion of controlled HIV infection as in (1) and (2), plus
documentation of no missed clinic appointments during
HCV staging process; and (7) alcohol sobriety for at
least 6 months prior to HCV treatment initiation.
Clinical HCV treatment initiation decisions were made
following multidisciplinary review of medical, psychia-
tric, social and substance abuse assessments. Psychiatric
care included pre-emptive use of antidepressants when
indicated. Treatment initiation decisions were made,
however, without clinician knowledge of HCV symptom
inventory scores.
Study procedures and data collection
After recording of vital signs, a patient was placed in the
exam room. While the patient waited to be seen by one of
our team clinicians, our substance counselor met with the
patient, explained and administered a computer assisted
survey. If the patient had additional questions, their clini-
cians answered these queries; prior to the patient’sf i n a l
completion of the computer assisted inventory. The survey
was administered online using Remark Web Survey version
5.0 (Gravic Inc., Malvern, Pennsylvania) using the exam
room computer. The first page of the survey contained the
Center for Epidemiologic Studies Depression Scale (CES-D)
questions. The second page contains the hepatitis symptom
inventory questions. Each symptom item includes a 6-cate-
gory, Likert scaled symptom severity response, ranging
from 0 (symptom absent) to 5 (symptom very severe). No
other battery of questions was administered. Surveys were
self-administered by patientsa n dt o o k ,o na v e r a g e ,f i v e
minutes to complete. It was the responsibility of the evalu-
ating clinician to verify that willing patients completed the
symptom inventory. Data was stored on a secure intranet
server of the study clinic.
Electronic medical records from each study participant
were reviewed to abstract information regarding demo-
graphic characteristics, substance use, psychiatry history,
and relevant clinical data.
Instruments and frequency of measurement
The 41-HCV symptom inventory was chosen because it
was already in use as monitoring tool of side effects of
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tion [18]. The HCV symptom inventory is a modified
version of the “Neurotoxicity Rating Scale” [19]. This
scale includes items scored from 0 ("not present”)t o4
("extremely severe”)m e a s u r i n gt h es e v e r i t yo fv a r i o u s
psychiatric, cognitive, neurovegetative and somatic
symptoms known to be induced by interferon therapy
[19]. Scores range from 0 to 148; the mean [± SD] score
in patients in a prior study who discontinued interferon
alfa therapy due to severe depression or neurotoxicity
was 42.6 ± 26.2 [20].
The CES-D is a 20-item, self-report, depression inven-
tory with each item scored on a scale of 1-4 (higher
scores indicate more depressive symptoms). The CES-D
has been validated among HCV infected people and was
shown to have a four-factor structure: negative effect,
positive effect, depressed effect, and somatic, with the
last factor being composed of 3 items. Total score can
range from 0 to 60; a score of 16 or greater generally is
considered the cutoff score associated with depressive
symptoms [21].
Both the Center for Epidemiologic Studies Depression
Scale (CES-D) and HCV symptom inventory were admi-
nistered during the first clinic visit (baseline) and at sub-
sequent study clinic visits of the HCV clinical staging
process. Patients who subsequently initiated HCV ther-
apy were seen at least monthly according to our clinic
protocol with completion of surveys at every clinic visit.
Statistical analysis
Continuous variables are expressed as means ± SD. Dif-
ferences between groups were compared using the
Mann-Whitney U test and Fisher’s exact tests for con-
tinuous and categorical values, respectively. Principal
component factor analysis with varimax rotation was
performed to determine the factor structure of the HCV
symptom inventory and to develop subscales of suitable
internal consistency and reliability. Only factors with
eigenvalues greater than 1.5 were retained for analysis.
An item required factor loadings greater than 0.50 in
order to be included in a subscale. Subscale reliability
was estimated with Cronbach’s alpha. Convergent valid-
ity of the HCV symptom inventory was assessed by
examining the joint distribution and correlation between
the HCV symptom inventory (total and subscale scores)
and a previously validated depression screening tool
(CES-D). Differences between dependent correlations
involving CES-D and each of the symptom subscales
were estimated using bootstrap resampling with 1000
replications (Stata bootcor procedure). Predictive validity
of HCV symptom inventory was assessed in two ways:
(1) in the prediction of the clinical decision to initiate
HCV treatment based on pre-treatment assessment; and
(2) in longitudinal changes in HCV symptom inventory
scores while on therapy using generalized estimating
equations (GEE). The null hypotheses for both predic-
tive validation components were, respectively, that: (1)
symptom scores were unrelated to treatment decisions
after taking into account established indications for
treatment initiation; and (2) HCV symptom inventory
scores do not change on HCV treatment. To identify
baseline predictors of HCV treatment initiation we used
analysis of variance and Fisher’s test for continuous and
categorical variables, respectively. Significant (p > 0.10)
bivariate predictors were entered into stepwise multiple
logistic regression analyses. Statistical significance for all
tests was defined as a two-tailed p < 0.05. Analyses were
performed using Stata version 11.0 (Stata Corp., College
Station, Texas, USA).
Results
Between 1 April 2008 and 31 July 2010, 193 HIV-
infected individuals naïve for HCV therapy were referred
to our clinic for assessment of HCV treatment eligibility.
Sixty-seven patients were not enrolled in the study for
the following reasons: (1)cirrhosis and evidence of portal
hypertension (n = 17); (2) declined staging procedures
and preferred to wait for new HCV therapies (n = 15);
(3) omission of survey completion during early months
on study implementation (n = 13); (4) declined any
medical treatment or evaluation (n = 9); (5) HCV anti-
body positive and HCV RNA negative and did not need
HCV therapy (n = 7); and (6) transferring care to a dif-
ferent city and clinical staging could not be completed
( n=6 ) .T h ef i n a ls t u d ys a m p l ew a s1 2 6H C V / H I Vc o -
infected patients that completed the HCV symptom
inventory and clinical staging process for HCV treat-
ment eligibility. Median age was 49. By HIV risk factor,
41% were intravenous drug users, 37% men who have
sex with men, and 14% acquired HIV through hetero-
sexual transmission. By HCV risk factor, 75% were
intravenous drug users, 23% men who had sex with men
and 2% hemophilia patients. Most patients (59%) had
prior diagnosis of major depression or bipolar disorder,
of whom 31% were taking psychotropic medications at
time of medical of assessment. Active use of illicit drugs
was reported by 15% of patients, most of them reporting
intravenous drugs (15 of 19 patients).
HCV symptom inventory factor structure and convergent
validity
Factor analysis of the 41-items HCV symptom inventory
yielded a three-factor structure with eigenvalues ≥ 3.2,
explaining 60% of the total variance. The factor account-
ing for the highest proportion of the variance (28%)
included 14 items with strong loadings that corre-
sponded to questions related to sadness, mood swings,
anxiety, irritability, anhedonia, lack of concentration,
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‘neuropsychiatric symptoms’ factor. The second included
11 items that explained 22% of the variance and corre-
sponded to questions related to body aches, dizziness,
skin/hair changes, and nausea and was therefore named
‘somatic symptoms’ factor. The third, with high loadings
for insomnia and interrupted sleep related questions
explained 11% of the variance and was termed the ‘sleep
symptoms’ factor. The final determination regarding
scale inclusion of items was based on factor loadings
and investigator judgment regarding content and face
validity for a putative subscale construct (Table 1).
Internal consistency reliability estimates of the 3 sub-
scales were 0.93, 0.89 and 0.79 for neuropsychiatric,
somatic and sleep symptoms, respectively. To examine
convergent validity of the HCV symptom inventory sub-
scales we compared the correlation between the HCV
symptom inventory scores and CES-D scores. There was
a strong correlation between the total symptom score
and CES-D before HCV treatment initiation, with symp-
toms reported in the inventory accounting for 64% of
the variability in the CES-D scores, r = 0.80 with 95%
confidence interval(CI) 0.70 to 0.85, p < 0.00001 (Figure
1). Neuropsychiatric, somatic and sleep subscale score
correlations (r) with CES-D scores were 0.88 (95% CI:
0.81 to 0.91), 0.51 (95% CI: 0.34 to 0.64) and 0.50 (95%
CI: 0.32 to 0.63), respectively. Bootstrap comparison
showed that the correlation of neuropsychiatric symp-
tom score with CES-D scores was significantly different
from the correlations of somatic and sleep symptom
scores with CES-D scores (p = 0.001). However the
magnitude of somatic and sleep symptoms correlations
with CES-D did not differ significantly from one another
(p = 0.89).
HCV symptom predictive validity
Examination of the predictive validity of the HCV symp-
tom inventory was conducted using generalized estimating
equations modeling of the data scores for the 32 HCV/HIV
patients who initiated HCV therapy. The median number
of times that the symptom inventory was completed by
each patient while on HCV therapy was 6 (range: 1-14). As
shown in Table 2, patients developed worsening somatic
and neuropsychiatric symptoms after HCV therapy initia-
tion but not worsening sleep symptoms or CES-D scores.
When the HCV symptom inventory sum scores were
observed individually, they also worsened after HCV ther-
apy initiation as shown in Figure 2. The coefficients (Bo,
B1) of the models presented in Table 2 may be interpreted
using the following example for HCV symptom inventory
sum score as the dependent variable. For patients not on
HCV therapy (reference group), the average total symptom
score was 53.27. For patients on HCV therapy the average
total symptom score was 60.19 (53.27 + 6.92).
Predictors of HCV therapy
During the study period 32 HIV-infected patients
initiated therapy for HCV. Of those treated, 63% (n = 20)
had liver biopsies. Using the Modified Knodell Score,
liver biopsy showed absent/mild (F0-F2), moderate (F3-
F4), and advanced fibrosis (F5) in 9, 8 and 3 patients
respectively. Comparing those treated to the untreated,
the median [range] ALT values were 52 [22-196] and 57
[23-302], respectively (p = 0.76). In bivariate analyses,
there were no differences in HCV genotype or viral load,
HIV risk factor, CD4 cell count, race/ethnicity, propor-
tion of patients with psychiatric histories, or prior or cur-
rent illicit substance use comparing HCV treated to not
treated patients (Table 3). However, when race/ethnicity
was categorized as a dichotomous variable (white vs.
non-white), whites were more likely to initiate HCV ther-
apy (p = 0.01), (Table 3). Of note, patients with a history
of neuropsychiatric disease who were considered not eli-
gible for HCV therapy had higher symptom sum scores
than their counterparts with prior psychiatric histories
who initiated HCV treatment (78.7 vs. 59.6, p = 0.009).
In unadjusted analysis, predictors of HCV therapy initia-
tion were lower HIV log10 RNA (1.66 vs. 2.12, p = 0.01),
lower total symptom score (56.2 vs. 72.5, p = 0.0001),
neuropsychiatric score (19.3 vs. 27.6, p = 0.00006),
somatic score (18.9 vs. 16.1, p = 0.0001) sleep score (3.2
v s .4 . 3 ,p=0 . 0 4 ) ,a n dl o w e rC E S - Ds c o r e( 7 . 7v s .1 7 . 7 ,p
= 0.0003) (Table 3). Backward stepwise multiple logistic
regression analysis was used to identify independent pre-
dictors of treatment initiation in two models. The first
model included only the HCV symptom inventory sum
and subscale scores. The second model included all vari-
ables found to be significant (p < 0.10) in bivariate analy-
sis (including race/ethnicity as dichotomous variable). In
both stepwise logistic models, the most important predic-
tor of HCV treatment initiation was neuropsychiatric
symptom score, with an odds ratio (OR) of 0.88 (95% CI:
0.81 to 0.96, p = 0.002) in the first model, and OR: 0.86
(95% CI 0.79 to 0.94, p = 0.001) in the second model for
each unit of increment in neuropsychiatric symptom
score. HIV log10 RNA was also retained in the second
model and was inversely associated with HCV treatment
initiation with OR: 0.03 (95%CI: 0.0004 to 2.24, p = 0.11)
for each increment of 1 log10 of HIV RNA.
Discussion
T h ep r e s e n ts t u d ye x a m i n e daquantitative assessment
of symptoms that were hypothesized to be associated
with the decision to initiate or defer HCV treatment
initiation, independent of standard of care clinical con-
siderations. The assessment was part of a multidisciplin-
ary approach implemented within a comprehensive HIV
p r i m a r yc a r ec l i n i cc a r i n gf o rm o r et h a n3 , 0 0 0p a t i e n t s
of which 27% are co-infected with HCV.
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tom questionnaire completed just prior to the patient-
provider encounter. Patient reported symptoms are
important components of comprehensive clinical assess-
ment [22]. Recently, a study of cancer patients found
that internet assessment of different symptoms supple-
ment traditional office visit discussions and fill
important gaps in clinicians’ knowledge, significantly
improving patient safety and quality of care [23]. This
suggests improvement in sensitivity of ascertainment
when traditional methods are replaced by technologi-
cally enhanced symptoms assessment [24].
The study results suggest that the HCV symptom
inventory could be a useful tool for consideration of
Table 1 Factor loadings in each of the items of the symptom inventory on the three factors extracted, after varimax
rotation
Symptoms Neuropsychiatric symptoms Somatic symptoms Sleep symptoms
Anxiety 0.52
a 0.18 0.32
Cough or nasal congestion 0.24 0.24 0.01
Sadness/depression 0.71
a 0.06 0.30
Restlessness 0.52
a 0.19 0.42
No interest in activities 0.72
a 0.05 0.32
Difficulty making decisions 0.74
a 0.14 0.23
Strange thoughts 0.62
a -0.14 0.37
All-over sick feeling 0.42 0.63
a 0.19
Difficulty getting to sleep 0.22 0.29 0.68
a
Difficulty staying asleep 0.25 0.28 0.70
a
Sleeping too much 0.45 0.10 -0.25
Nausea 0.38 0.55
a 0.12
Vomiting 0.10 0.38 0.26
Loss of appetite 0.41
a 0.15 0.10
Tiredness/fatigue 0.55
a 0.38 0.15
Distractibility 0.75
a 0.33 0.04
Body aches 0.26 0.72
a 0.26
Joint pain 0.24 0.63
a 0.30
Chest pain 0.14 0.64
a 0.12
Other pain 0.09 0.52
a 0.27
Episodes of confusion 0.70
a 0.31 0.07
Word finding problem 0.59
a 0.33 -0.04
Memory problem 0.66
a 0.36 0.05
Irritability 0.57
a 0.21 0.44
Decreased motivation 0.73
a 0.21 0.13
Hallucinations 0.34 -0.01 0.52
a
Lack of emotions 0.47 0.12 0.10
Mood swings 0.57
a 0.32 0.47
Slowed movements 0.30 0.65
a -0.03
Tremor/shakiness 0.16 0.38 0.28
Walking problems 0.14 0.65
a 0.33
Vision problems 0.02 0.47 0.04
Bladder problems 0.29 0.36 0.20
Loss of interest in sex 0.47 0.21 0.07
Fever 0.04 0.37 0.18
Headaches 0.50
a 0.39 0.21
Nightmares/dreams 0.38 0.43 0.25
Shortness of breath 0.59
a 0.47 -0.13
Rash/skin change/itching 0.19 0.68
a -0.02
Change in hair -0.001 0.51
a 0.29
Dizziness 0.32 0.55
a 0.13
a = Item included in final factor structure.
Cachay et al. AIDS Research and Therapy 2011, 8:29
http://www.aidsrestherapy.com/content/8/1/29
Page 5 of 9HCV treatment eligibility in HIV infected patients.
The HCV symptom inventory has a meaningful inter-
nal structure with excellent reliability as well as initial
evidence supporting construct, convergent and pre-
dictive validity. The underlying structure of the inven-
tory was factor analyzed into 3 primary constructs
reflecting neuropsychiatric, somatic and sleep
symptoms.
Similar to other reports [5,6,25,26], the present study
found that severe neuropsychiatric symptoms and high
CES-D scores at baseline were associated with indepen-
dent judgment regarding treatment candidacy, perhaps
due to clinician awareness of the likely worsening effect
that interferon may have on neuropsychiatric symptoms
[27,28]. A novel observation was that patients with
worse somatic and sleep symptoms at baseline were less
Figure 1 Correlation matrix displaying the correlations among symptom sum and subscale scores with CES-D scores at baseline of
HIV-infected individuals referred for assessment of hepatitis C treatment eligibility.
Table 2 Unadjusted Generalized estimating equations models of treatment period (pre therapy vs. on HCV therapy)
Model Score B0
(Constant)
B1
(coefficient)
95% confidence interval P
1 Sum symptoms 53.27 6.92 2.23 to 11.61 0.004
2 CES-D 7.31 1.86 -0.01 to 9.36 0.05
3 Neuropsychiatric symptoms 18.26 2.55 0.73 to 4.38 0.006
4 Somatic symptoms 14.30 2.57 1.01 to 4.14 0.001
5 Sleep symptoms 2.93 0.45 -0.08 to 0.98 0.09
Effects on symptoms and CES-D scales cores (n = 31).
CES-D = Center for Epidemiologic Studies Depression Scale
Each model had the form:
score = B0 +B 1 (treatment period); where treatment = 1 if on therapy and 0 if before therapy.
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results highlight the importance of baseline screening
for somatic and sleep symptoms, particularly those that
are known to be aggravated by HCV therapy: body
aches, different somatic non-specific pains, skin com-
plaints and nausea. Our results are in agreement with
prior results validating the CES-D scale for HCV ther-
apy and also identifying a somatic component in its
underlying structure [21]. However, the CES-D somatic
component has only 3 items (poor appetite, keep in
mind what I was doing, and everything an effort to do)
and does not focus specifically on comprehensive symp-
tom evaluation.
The HCV symptom inventory could be viewed as a
screening tool complementary to a well validated
depression scale such as CES-D during HCV treatment
eligibility assessment. Recognizing, acknowledging and
medically assessing the presence of somatic and sleep
symptoms in addition to neuropsychiatric screening
prior to HCV therapy in HIV patients may enhance
patient engagement in care and compliance with HCV
therapy.
We found no effect of HCV genotype, viral load (both
of which are predictors of HCV treatment response),
CD4 cell count, HIV risk factor and gender on HCV
treatment candidacy in the present study. This is consis-
tent with the inclusive approach of the study team to
treat as many HCV/HIV co-infected patients as possible.
Our program aim is to also treat homeless individuals,
patients with past and current substance use, and those
with ongoing psychiatric conditions as long as they
remain engaged in care. Consistent with prior reports
[5,7], in our cohort whites tend to be treated more fre-
quently that non-whites in unadjusted analysis. How-
ever, after adjusting for HIV viral load and
neuropsychiatric symptom score, race was no longer
associated with a treatment initiation decision. This
likely reflected the clinician’s perception of the
decreased likelihood of HCV treatment response in
non-white individuals when other known factors are
taken in consideration [29]. The study was conducted
before the interleukin-28B gene polymorphism was
widely available as a screening tool to further character-
ize likelihood of HCV treatment response among non-
white patients [30,31]. We noted that patients with
higher HIV viral loads were less likely to be treated, but
these patients had recently re-initiated HIV therapy.
Interestingly, we did not find a significant negative
impact following HCV therapy initiation in sleep symp-
toms or CES-D scores; these treatment-emergent symp-
toms were routinely treated by either the treatment
team or the primary care providers, thus attenuating the
expected effects on self reported depressive and sleep
symptoms.
Inference from the study is subject to several limita-
tions. First, since only 74% of patients completed the
symptom inventory at each HCV staging visit, bias by
unmeasured patients with worsening symptoms cannot
be excluded. However, there was no difference in the
mean symptom scores between patients who completed
the symptom inventory at every clinic visit and those
who completed the inventory occasionally (48.3 vs. 45.1,
p = 0.79). We believe the missing inventories were more
prevalent at the beginning of the implementation of our
new clinic model when patients were not familiar with
the process. We have subsequently implemented a pro-
cedure whereby the medical assistant immediately noti-
fies our substance abuse counselor when a patient is
placed in the exam room to avoid delays in the comple-
tion of the symptom inventory. Second, we recognize
that both measured and unmeasured co-morbidities
may increase variability in symptom scores. However,
Figure 2 Illustration of Individuals total sum symptom scores of HIV-infected patients before Hepatitis C treatment initiation (Panel A)
and while on hepatitis C therapy (panel B).
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extent to which systematically measured symptomatol-
ogy predicts treatment initiation decisions, while our
longer term objective is to assess the symptom inven-
tory as a predictor of adherence and treatment com-
p l e t i o n .T h i r d ,a l t h o u g ht h es a m p l es i z ec o u l db e
considered relatively small (n = 126) it was sufficient
to demonstrate the reliability and preliminary validity
of the symptom inventory. Fourth, although stepwise
multiple regression methods are popular in medical
research, we acknowledge that they may have poten-
tially serious shortcomings for valid inference [32]. As
we described above this is an exploratory analysis to
validate the symptom inventory and not a randomized
controlled clinical trial. Future longitudinal trials are
needed to confirm of our model conclusions. Finally,
because the symptom inventory was performed only in
English, inference regarding the observed findings is
limited only to our English-speaking population. How-
ever, we recently have implemented a Spanish version
of the symptom inventory for our patients when
needed.
In conclusion, a 41 item hepatitis-related symptom
inventory was found to have a clinically meaningful 3-
factor structure with excellent internal consistency relia-
bility and predictive validity. Both symptom and CES-D
scores were predictive of treatment initiation decisions.
Future research will identify whether the symptom
inventory is useful in predicting adherence and treat-
ment completion.
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Table 3 Bivariate analyses displaying predictors of
Hepatitis C therapy in HIV co-infected patients
Variable HCV treatment
subset
P
Value
No
(n = 94)
Yes
(n = 32)
Gender:
Female 14 7 0.56
Male 79 25
Race/ethnicity:
White 55 11 0.09
Hispanic 20 9
Black 17 10
Unknown/other 2 2
Race/ethnicity, dichotomized:
White 55 11 0.02
Non-white 39 21
HIV risk factor:
Gay/bisexual 34 13 0.96
Heterosexual 11 3
Intravenous drug use 39 13
Hemophiliac 1 0
Unknown/other 0 3
CD4 cell count (×10
6/l), mean (sd) 488(294) 478(272) 0.61
HIV log10 viral load, mean(sd) 2.12
(0.96)
1.66
(0.07)
0.01
HCV log10 RNA, mean (sd) 6.36
(1.30)
6.27
(1.12)
0.63
HCV genotype:
Genotype 2 & 3 14 6 0.65
Genotype 1 & 4 74 25
History of neuropsychiatric disease (%) 56 (60) 18 (56) 0.74
Ever use illicit substance (%) 87 (93) 28 (88) 0.38
Ongoing illicit substance use (%) 12 (13) 3 (9) 0.61
Total symptoms score, mean (sd) 73(25) 56(10) 0.002
Neuropsychiatric symptoms score, mean
(sd)
28(11) 19(4) 0.00006
Somatic symptoms score, mean (sd) 19(8) 16(5) 0.0001
Sleep symptoms score, mean (sd) 4(3) 3(2) 0.04
CES-D score, mean (sd) 17(13) 8(7) 0.00003
CES-D = Center for Epidemiologic Studies Depression Scale.
Cachay et al. AIDS Research and Therapy 2011, 8:29
http://www.aidsrestherapy.com/content/8/1/29
Page 8 of 9of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005,
42:615-24.
5. Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK: Rates and predictors
of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment
Pharmacol Ther 2006, 24:585-91.
6. Scott JD, Wald A, Kitahata M, Krantz E, Drolette L, Corey L, Wang CC:
Hepatitis C virus is infrequently evaluated and treated in an urban HIV
clinic population. AIDS Patient Care STDS 2009, 23:925-9.
7. Vellozzi C, Buchacz K, Baker R, Spradling PR, Richardson J, Moorman A,
Tedaldi E, Durham M, Ward J, Brooks JT, HOPS Investigators: Treatment of
hepatitis C virus (HCV) infection in patients coinfected with HIV in the
HIV Outpatient Study (HOPS), 1999-2007. J Viral Hepat 2011, 18:316-24.
8. Fleming CA, Tumilty S, Murray JE, Nunes D: Challenges in the treatment of
patients coinfected with HIV and hepatitis C virus: need for team care.
Clin Infect Dis 2005, 40:S349-54.
9. Goulet JL, Fultz SL, McGinnis KA, Justice AC: Relative prevalence of
comorbidities and treatment contraindications in HIV-mono-infected
and HIV/HCV-co-infected veterans. AIDS 2005, 19:S99-105.
10. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR: Hepatitis C virus
infection in San Francisco’s HIV-infected urban poor. J Gen Intern Med
2004, 19:357-65.
11. Golden J, O’Dwyer AM, Conroy RM: Depression and anxiety in patients
with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp
Psychiatry 2005, 27:431-8.
12. Yoon JC, Crane PK, Ciechanowski PS, Harrington RD, Kitahata MM,
Crane HM: Somatic symptoms and the association between hepatitis C
infection and depression in HIV-infected patients. AIDS Care 2011.
13. Sulkowski MS, Cheever LW, Spach DH: A Guide for Evaluation and
Treatment of Hepatitis C in Adults Coinfected with HIV. US Department of
Health and Human Services 2011 [http://hab.hrsa.gov/deliverhivaidscare/files/
hepccoinfectguide2011.pdf].
14. Taylor LE: Delivering care to injection drug users coinfected with HIV
and hepatitis C virus. Clin Infect Dis 2005, 40:S355-61.
15. Taylor LE, Bowman SE, Chapman S, Zaller N, Stein MD, Cioe PA,
Maynard MA, McGovern BH: Treatment for hepatitis C virus genotype 1
infection in HIV-infected individuals on methadone maintenance
therapy. Drug Alcohol Depend 2011, 116:233-7.
16. Voigt E, Schulz C, Klausen G, Goelz J, Mauss S, Schmutz G, Jessen H,
Weitner L, Mutz A, Schranz D, Rockstroh JK, Kaad Study Group: Pegylated
interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis
C in HIV-coinfected patients. J Infect 2006, 53:36-42.
17. Butt AA, McGinnis KA, Skanderson M, Justice AC: Hepatitis C treatment
completion rates in routine clinical care. Liver Int 2010, 30:240-50.
18. Bonacini M, Morris W, Huilgol V, Gish RG: The Hepatitis C Treatment Side
Effect Rating Scale from the appendix 13 of the Primary care case
management clinical pathway for the treatment of hepatitis C (version
5.0) from California Pacific Medical Center.[http://www.dshs.state.tx.us/
idcu/disease/hepatitis/hepatitis_c/professional/physicians/
hcv_primarycare_management.pdf].
19. Valentine AD, Meyers CA, Talpaz M: Treatment of neurotoxic side effects
of interferon-alpha with naltrexone. Cancer Invest 1995, 13:561-6.
20. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S,
Goodkin RS, Greiner K, Nemeroff CB, Miller AH: Paroxetine for the
prevention of depression induced by high-dose interferon alfa. N Engl J
Med 2001, 344:961-6.
21. Clark CH, Mahoney JS, Clark DJ, Eriksen LR: Screening for depression in a
hepatitis C population: the reliability and validity of the Center for
Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs 2002,
40:361-9.
22. Justice AC, Chang CH, Rabeneck L, Zackin R: Clinical importance of
provider-reported HIV symptoms compared with patient-report. Med
Care 2001, 39:397-408.
23. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J,
Farquhar R, Scher HI, McCabe M, Schrag D: Long-term toxicity monitoring
via electronic patient-reported outcomes in patients receiving
chemotherapy. J Clin Oncol 2007, 25:5374-80.
24. Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-
Seymour M, Bush N, Karras BT, Lober WB, McCorkle R: Enhancing Patient-
Provider Communication With the Electronic Self-Report Assessment for
Cancer: A Randomized Trial. J Clin Oncol 2011, 29:1029-35.
25. Backus LI, Boothroyd DB, Phillips BR, Mole LA: Pretreatment assessment
and predictors of hepatitis C virus treatment in US veterans coinfected
with HIV and hepatitis C virus. J Viral Hepat 2006, 13:799-810.
26. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK: Rate
and predictors of treatment prescription for hepatitis C. Gut 2007,
56:385-9.
27. Dell’Osso L, Pini S, Maggi L, Rucci P, Del Debbio A, Carlini M, Baldini A,
Ferrari G, Manca E, Beverini E, Amore M, Scarallo V, Semeraro Q, Brunetto M,
Bonino F, Maj M: Subthreshold mania as predictor of depression during
interferon treatment in HCV+ patients without current or lifetime
psychiatric disorders. J Psychosom Res 2007, 62:349-55.
28. Myint AM, Schwarz MJ, Steinbusch HW, Leonard BE: Neuropsychiatric
disorders related to interferon and interleukins treatment. Metab Brain
Dis 2009, 24:55-68.
29. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N,
Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD, Virahep-C Study
Group: Peginterferon and ribavirin treatment in African American and
Caucasian American patients with hepatitis C genotype 1.
Gastroenterology 2006, 131:470-7.
30. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL,
Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB:
Genetic variation in IL28B predicts hepatitis C treatment-induced viral
clearance. Nature 2009, 461:399-401.
31. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M,
Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF,
Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D,
Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F,
Telenti A, Bochud PY: Genetic variation in IL28B is associated with
chronic hepatitis C and treatment failure: a genome-wide association
study. Gastroenterology 2010, 138:1338-45, e7.
32. Steyerberg EW, Eijkemans MJ, Habbema JD: Stepwise selection in small
data sets: a simulation study of bias in logistic regression analysis. J Clin
Epidemiol 1999, 52:935-42.
doi:10.1186/1742-6405-8-29
Cite this article as: Cachay et al.: Reliability and predictive validity of a
hepatitis-related symptom inventory in HIV-infected individuals referred
for Hepatitis C treatment. AIDS Research and Therapy 2011 8:29.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cachay et al. AIDS Research and Therapy 2011, 8:29
http://www.aidsrestherapy.com/content/8/1/29
Page 9 of 9